SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-004105 to vTv Therapeutics Inc. (VTVT) (CIK 0001641489) (VTVT)

vTv Therapeutics Inc. (VTVT) (CIK 0001641489)
Date: April 16, 2024 · CIK: 0001641489 · Accession: 0000000000-24-004105

AI Filing Summary & Sentiment

File numbers found in text: 333-278612

Date
April 15, 2024
Author
Not clearly detected
Form
UPLOAD
Company
vTv Therapeutics Inc. (VTVT) (CIK 0001641489)

Letter

United States securities and exchange commission logo April 15, 2024 Steven Tuch Chief Financial Officer vTv Therapeutics Inc. 3980 Premier Drive, Suite 310 High Point, NC 27265 Re:vTv Therapeutics Inc. Registration Statement on Form S-3 Filed April 10, 2024 File No. 333-278612 Dear Steven Tuch: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Rosenthal, Esq.

Show Raw Text
United States securities and exchange commission logo
April 15, 2024
Steven Tuch
Chief Financial Officer
vTv Therapeutics Inc.
3980 Premier Drive, Suite 310
High Point, NC 27265
Re:vTv Therapeutics Inc.
Registration Statement on Form S-3
Filed April 10, 2024
File No. 333-278612
Dear Steven Tuch:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       David Rosenthal, Esq.